Search clinical trials for: CD3/CD19 negative allogeneic hematopoietic stem cells (HSCT)

Total 30991 results

PETHEMA Foundation

Terminated

PETHEMA-BLIN-01/PET069014 (BLIN-01)

Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL

Spain
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 (CART19)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Children's Hospital Los Angeles

Completed

Ultra-high Dose Vitamin D for HSCT

Hematopoietic Stem Cell Transplant

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma of Soft Tissue

China
Seattle Children's Hospital

Active, not recruiting

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

CD 19+ Acute Leukemia

United States
Massachusetts General Hospital

Completed

Fecal Microbiota Transplantation After HSCT

Bone Marrow Transplantation

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Positive Psychology Intervention In HSCT (PATH-3)

Hematopoietic/Lymphoid Cancer | Hematologic Malignancy | Blood Cancer

United States
European Society for Blood and Marrow Transplantation

Completed

Allo SCT in Amyloidosis Non-interventional Study

AL Amyloidosis

Germany, France, Switzerland
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Multiple Myeloma

China
University of Florida

Completed

UF-BMT-HSCT-001: A Non-Interventional Study Evaluating Diet in HSCT Survivors

Hematopoietic Neoplasm

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

Autoimmune Diseases | Sjogren's Syndrome

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

Autoimmune Diseases | Systemic Lupus Erythematosus

China
Brigham and Women's Hospital

Completed

Oral OKT3 for the Treatment of Active Ulcerative Colitis

Ulcerative Colitis

United States
Peking University People's Hospital

Recruiting

RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT

Myelodysplastic Syndromes

China
St. Petersburg State Pavlov Medical University

Active, not recruiting

Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy

Hematologic Malignancy

Russian Federation
medac GmbH
Synteract, Inc.

Recruiting

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML) | Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

United States
GlaxoSmithKline
Juvenile Diabetes Research Foundation

Completed

Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2 (DEFEND-2)

Diabetes Mellitus, Type 1

Italy
Shanghai Tongji Hospital, Tongji University School...

Recruiting

Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.

B Cell Malignancies

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

Autoimmune Diseases | Lupus Nephritis | Immune Nephritis

China
Triumvira Immunologics, Inc.

Withdrawn

Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma (TACTIC-19)

Lymphoma, B-Cell
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Unknown

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Timmune Biotech Inc.
Hunan Provincial People's Hospital

Unknown

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 (Trident19-H)

Non-hodgkin Lymphoma,B Cell

China
First Affiliated Hospital of Guangxi Medical University
Peking University People's Hospital; Ruijin Hospital; The Affiliated Hospital... and other collaborators

Recruiting

Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study

Thalassemia Major

China
Regeneron Pharmaceuticals

Recruiting

Study for Desensitization of Chronic Kidney Disease in Adult Patients in Need of a Kidney Transplant Who Are Highly Sensitized to Human Leukocyte Antigen

Chronic Kidney Disease (CKD)

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis | Idiopathic Inflammatory Myopathies | Primary Sjögren Syndrome | IgG4 Related Disease

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Lymphoma, B-Cell

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Withdrawn

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic Leukemia

China
Juventas Cell Therapy Ltd.

Recruiting

Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases

Lupus Erythematosus, Systemic

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

B-cell Non Hodgkin Lymphoma

China
MorphoSys AG

Completed

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin Lymphoma

United States, Belgium, Germany, Hungary, Italy, Poland, Spain
University College, London

Active, not recruiting

CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies

Burkitt Lymphoma | Acute Lymphoblastic Leukemia

United Kingdom
Shandong Provincial Hospital

Recruiting

Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT

Stem Cell Transplant Complications

China
Assiut University

Unknown

Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura

Immune Thrombocytopenia
Xijing Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Diffuse Large B Cell Lymphoma

China
Chimerix

Completed

Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease

Adenovirus Disease

United States
Assiut University

Not yet recruiting

Expression of CD19 Complex in Lymphoproliferative Disorders (CD19)

Lymphoproliferative Disorders
Chembrain LTD
University of Oulu; Jyväskylä Central Hospital; Apollo Hospital, New Delhi, India

Active, not recruiting

The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients (CARTREMENDOUS)

Glioblastoma | Glioblastoma Multiforme | Glioma, Malignant

Finland, India
TC Biopharm

Not yet recruiting

ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML (ACHIEVE2)

Acute Myeloid Leukemia | Myelodysplastic Syndromes
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Adult B Acute Lymphoblastic Leukemia

China
Genmab
AbbVie

Recruiting

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)

Small Lymphocytic Lymphoma | Richter's Syndrome | Relapsed/Refractory Chronic Lymphocytic Leukemia

United States, Belgium, Netherlands, Spain, Italy, Australia, Israel, France, Denmark, Czechia, Germany, United Kingdom
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
The First Affiliated Hospital of Nanchang University

Unknown

Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Sinobioway Cell Therapy Co., Ltd.
Jiangsu Cancer Institute & Hospital

Unknown

Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma (EECPL)

Lymphoma

China
Imugene Limited

Recruiting

A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) (OASIS)

Solid Tumor, Adult

United States
920th Hospital of Joint Logistics Support Force...

Recruiting

Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

B-cell Acute Lymphoblastic Leukemia | B-ALL

China
AstraZeneca

Recruiting

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin Lymphoma

Korea, Republic of, United States, Japan, Taiwan, Australia
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen... and other collaborators

Recruiting

Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT

Allogeneic Hematopoietic Stem Cell Transplantation | Conditioning | Myeloid Tumors

China

Search clinical trials for: CD3/CD19 negative allogeneic hematopoietic stem cells (HSCT)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations